Table 1.
Univariate and multivariate analyses of overall survival for 183 patients treated with fludarabine
| Analysis | n/N (%) | HR (95% CI) | P | Cumulative R2, % |
|---|---|---|---|---|
| Univariate | ||||
| Age > 70 y | 60/183 (33) | 2.28 (1.57-3.30) | < .001 | |
| Previous treatment | 64/183 (35) | 1.61 (1.11-2.33) | .012 | |
| Disease duration > 1 y | 72/183 (39) | 1.62 (1.12-2.34) | .010 | |
| B2M > 3 mg/L | 106/180 (59) | 1.56 (1.06-2.29) | .025 | |
| IgM < 4 g/dL | 75/183 (41) | 1.90 (1.09-2.28) | .015 | |
| LDH > ULN | 25/183 (14) | 1.69 (1.03-2.77) | .037 | |
| M-component < 2.2 g/dL | 32/116 (28) | 1.77 (1.05-3.00) | .034 | |
| ISSWM high risk* | 33/114 (29) | 2.64 (1.60-4.37) | < .001 | |
| Multivariate 1† | ||||
| Age > 70 y | 58/180 (32) | 2.29 (1.57-3.35) | < .001 | 11.702 |
| B2M > 3 mg/L | 106/180 (59) | 1.80 (1.21-2.67) | .004 | 15.594 |
| Previous treatment | 62/180 (34) | 1.73 (1.18-2.56) | .005 | 17.615 |
| LDH > ULN | 25/180 (14) | 1.77 (1.08-2.92) | .024 | 20.131 |
| Multivariate 2‡ | ||||
| Age > 70 y | 58/180 (32) | 2.32 (1.59-3.38) | < .001 | 11.702 |
| B2M > 3 mg/L | 106/180 (59) | 1.61 (1.09-2.37) | .016 | 15.594 |
| LDH > ULN | 25/180 (14) | 1.80 (1.09-2.95) | .020 | 17.571 |
| Multivariate 3§ | ||||
| ISSWM high risk | 33/114 (29) | 2.84 (1.71-4.72) | < .001 | 15.492 |
| LDH > ULN | 18/114 (16) | 2.25 (1.21-4.19) | .010 | 20.916 |
HR indicates hazard ratio; CI, confidence interval; B2M, β-2 microglobulin; IgM, immunoglobulin M; LDH, lactate dehydrogenase; M-component, M-protein component; ULN, upper limit of normal; and ISSWM, Waldenstrom macroglobulinemia international prognostic scoring system.
ISSWM high-risk category includes patients with at least 3 of the following: age greater than 65 years, Hb less than 11.5 g/dL, platelets less than 100 × 109/L, B2M greater than 3 mg/L, M-protein component greater than 7.0 g/dL (measured by densitometry).
Variables considered for multivariate 1 analysis included age greater than 70 years, previous treatment, disease duration greater than 1 year, CRP greater than 1 mg/L, Hb less than 12.0 g/dL, albumin less than 3.5 g/dL, B2M greater than 3 mg/L, IgM less than 4.0 g/dL, platelets less than 150 × 109/L, and LDH greater than ULN.
Multivariate 2 analysis included the same variables as multivariate 1, except previous treatment.
Variables considered for multivariate 3 analysis included ISSWM high risk, disease duration greater than 1 year, CRP greater than 1 mg/L, albumin less than 3.5 g/dL, and LDH greater than ULN.